CA2432945C - Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical - Google Patents

Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical Download PDF

Info

Publication number
CA2432945C
CA2432945C CA002432945A CA2432945A CA2432945C CA 2432945 C CA2432945 C CA 2432945C CA 002432945 A CA002432945 A CA 002432945A CA 2432945 A CA2432945 A CA 2432945A CA 2432945 C CA2432945 C CA 2432945C
Authority
CA
Canada
Prior art keywords
surgery
pyridoxine hydrochloride
doxylamine succinate
medicament
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002432945A
Other languages
English (en)
Other versions
CA2432945A1 (fr
Inventor
Brenda Reeve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Priority to CA002432945A priority Critical patent/CA2432945C/fr
Publication of CA2432945A1 publication Critical patent/CA2432945A1/fr
Application granted granted Critical
Publication of CA2432945C publication Critical patent/CA2432945C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium dans la prophylaxie et le traitement des nausées post-chirurgicaux. L'utilisation peut inclure l'administration en pré-opératoire, péri-opératoire ou post-opératoire du succinate de doxylamine et de chlorhydrate de pyridoxinium à un patient. VOIR FORMULE I VOIR FORMULE II
CA002432945A 2003-07-10 2003-07-10 Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical Expired - Fee Related CA2432945C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002432945A CA2432945C (fr) 2003-07-10 2003-07-10 Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002432945A CA2432945C (fr) 2003-07-10 2003-07-10 Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical

Publications (2)

Publication Number Publication Date
CA2432945A1 CA2432945A1 (fr) 2003-09-28
CA2432945C true CA2432945C (fr) 2004-11-23

Family

ID=28796494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002432945A Expired - Fee Related CA2432945C (fr) 2003-07-10 2003-07-10 Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical

Country Status (1)

Country Link
CA (1) CA2432945C (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761212A1 (fr) * 2011-12-07 2013-06-07 Pharmascience Inc. Formulation de pyridoxine et de doxylamine a action retardee sans delitant et son procede de fabrication
EP3337480A4 (fr) * 2015-08-17 2019-05-08 Aequus Pharmaceuticals Inc. Administration transdermique de succinate de doxylamine et de chlorhydrate de piridoxine
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
EP4440577A4 (fr) * 2021-11-30 2025-11-05 Ilko Ilac Sanayi Ve Ticaret A S Composition à libération retardée comprenant de la doxylamine et de la pyridoxine
EP4565232A1 (fr) * 2023-03-01 2025-06-11 Akums Drugs And Pharmaceuticals Limited Composition stable de type comprimé dans comprimé contre les nausées et vomissements pendant la grossesse

Also Published As

Publication number Publication date
CA2432945A1 (fr) 2003-09-28

Similar Documents

Publication Publication Date Title
KR20130045241A (ko) 구토방지제로서의 아미설프라이드의 용도
WO2003024450A1 (fr) Methodes de traitement des maladies a prions
US7259180B2 (en) Methods and compositions for treatment of macular and retinal disease
Tarkkila et al. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine
US20210196685A1 (en) Composition for eradicating helicobacter pylori
AU2022252766A1 (en) Treatment of hand eczema
JP2024144702A (ja) 網膜疾患の治療のための眼内または経口投与用医薬組成物
CA2432945C (fr) Utilisation d'un succinate de doxylamine et de chlorhydrate de pyridoxinium pour la prophylaxie et le traitement des nausees post-chirurgical
EP0689437B1 (fr) Utilisation de granisetron dans le traitement de la nausee et des vomissements postoperatoires
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
US20050004181A1 (en) Use of anti-emetic for pre and post operative care
US20030109566A1 (en) Remedial agent for optic nerve disease and the like
NZ249197A (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine in the preparation of medicaments for the treatment or prophylaxis of pain and/or oedema
US20110195987A1 (en) Treatment with cholinergic agonists
CA2840521C (fr) Composition pharmaceutique pour traiter l'ejaculation prematuree et procede pour traiter l'ejaculation prematuree
US20260027175A1 (en) Compositions and methods for treating a cognitive deficit
WO2008001360A2 (fr) Compositions et procédés destinés au traitement et à la prévention d'un reflux gastro-œsophagien pathologique
WO1998038997A1 (fr) Utilisation de la levobupivacaine en association avec des opioides ou des alfa2-agonistes comme anesthesiants ou analgesiques
KR102222271B1 (ko) 펙소페나딘 가용화 조성물
KR20190021180A (ko) 퇴행성 신경질환 치료용 복합 제형 조성물
US6162792A (en) Use of spiramycin for treating gastrointestinal disorders caused by H. pylori
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
CN118892483A (zh) 一种mpo酶抑制剂在制备预防和/或治疗神经炎症疾病药物中的应用
CN114515287A (zh) 一种由莫西沙星和西咪替丁制备的复方制剂及制备方法
CN120661505A (zh) 一种治疗幽门螺杆菌的复方制剂及其制备方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180710